{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:20:45Z","timestamp":1782890445461,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s11906-008-0059-1","type":"journal-article","created":{"date-parts":[[2008,10,29]],"date-time":"2008-10-29T17:12:34Z","timestamp":1225300354000},"page":"319-325","source":"Crossref","is-referenced-by-count":22,"title":["Insulin resistance and blood pressure"],"prefix":"10.1007","volume":"10","author":[{"given":"Sonya","family":"Addison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Stas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Sowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,30]]},"reference":[{"key":"59_CR1","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"S.M. Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, et al.: American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735\u20132752.","journal-title":"Circulation"},{"key":"59_CR2","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981\u20132997.","journal-title":"JAMA"},{"key":"59_CR3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206\u20131252.","journal-title":"Hypertension"},{"key":"59_CR4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1559-4564.2007.06368.x","volume":"2","author":"M.H. Schutta","year":"2007","unstructured":"Schutta MH: Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007, 2:124\u2013130.","journal-title":"J Cardiometab Syndr"},{"key":"59_CR5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.amjmed.2005.09.010","volume":"119","author":"J. Garcia-Puig","year":"2006","unstructured":"Garcia-Puig J, Ruilope LM, Luque M, et al.: Glucose metabolism in patients with essential hypertension. Am J Med 2006, 119:318\u2013326.","journal-title":"Am J Med"},{"key":"59_CR6","doi-asserted-by":"crossref","first-page":"H1597","DOI":"10.1152\/ajpheart.00026.2004","volume":"286","author":"J.R. Sowers","year":"2004","unstructured":"Sowers JR: Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597\u2013H1602.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"59_CR7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.0197-3118.2006.05455.x","volume":"1","author":"R. Nistala","year":"2006","unstructured":"Nistala, R, Stump CS: Skeletal muscle insulin resistance is fundamental to the cardiometabolic syndrome. J Cardiometab Syndr 2006, 1:47\u201352.","journal-title":"J Cardiometab Syndr"},{"key":"59_CR8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0889-8529(03)00070-7","volume":"32","author":"F. El-Atat","year":"2003","unstructured":"El-Atat F, Ashish A, Mcfarlane S, Sowers J: Obesity and hypertension. Endrinol Metab Clin N Am 2003, 32:823\u2013854.","journal-title":"Endrinol Metab Clin N Am"},{"key":"59_CR9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/HYPERTENSIONAHA.107.103077","volume":"51","author":"Y. Takata","year":"2008","unstructured":"Takata Y, Osawa H, Krata M, et al.: Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008, 51:534\u2013539.","journal-title":"Hypertension"},{"key":"59_CR10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11892-006-0061-4","volume":"6","author":"M. Diamant","year":"2006","unstructured":"Diamant M, Tushuizen M: The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD? Curr Diab Rep 2006, 6:279\u2013286.","journal-title":"Curr Diab Rep"},{"key":"59_CR11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.HYP.0000168046.19884.6a","volume":"46","author":"R. Clasen","year":"2005","unstructured":"Clasen R, Schupp M, Foryst-Ludwig A, et al.: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137\u2013143.","journal-title":"Hypertension"},{"key":"59_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.ten.0000264954.79260.c2","volume":"17","author":"J.R. Sowers","year":"2007","unstructured":"Sowers JR: The role of c-reactive protein in the metabolic syndrome and diabetes mellitus. Endocrinologist 2007, 17:163\u2013168.","journal-title":"Endocrinologist"},{"key":"59_CR13","doi-asserted-by":"crossref","first-page":"H2209","DOI":"10.1152\/ajpheart.00522.2007","volume":"293","author":"S.A. Cooper","year":"2007","unstructured":"Cooper SA, Whaley-Connell A, Habibi J, et al.: Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007, 293:H2209\u2013H2223.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"59_CR14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1751-7176.2008.08082.x","volume":"10","author":"S. Stas","year":"2008","unstructured":"Stas S, Whaley-Connell A, Sowers JR: Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008, 10:94\u201396.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"59_CR15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M. Brownlee","year":"2005","unstructured":"Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615\u20131625.","journal-title":"Diabetes"},{"key":"59_CR16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.amjhyper.2007.03.012","volume":"20","author":"F. Fallo","year":"2007","unstructured":"Fallo F, Della Mea P, Sonino N, et al.: Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007, 20:855\u2013861.","journal-title":"Am J Hypertens"},{"key":"59_CR17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ahj.2007.07.031","volume":"154","author":"B.G. Brouwer","year":"2007","unstructured":"Brouwer BG, Visseren FLJ, van der Graff Y: The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study. Am Heart J 2007, 154:1146\u20131152.","journal-title":"Am Heart J"},{"key":"59_CR18","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/eurheartj\/ehi394","volume":"26","author":"T.A. Lakka","year":"2005","unstructured":"Lakka TA, Lakka HM, Rankinen T, et al.: Effect of exercise training on plasma levels of c-reactive protein in healthy adults: the heritage family study. Eur Heart J 2005, 26:2018\u20132025.","journal-title":"Eur Heart J"},{"key":"59_CR19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/diacare.27.2.538","volume":"27","author":"N. McKeown","year":"2004","unstructured":"McKeown N, Meigs JB, Liu S, et al.: Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004, 27:538\u2013546.","journal-title":"Diabetes Care"},{"key":"59_CR20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.107.716159","volume":"117","author":"P.L. Lutsey","year":"2008","unstructured":"Lutsey PL, Steffen LM, Stevens J.: Dietary intake and the development of the metabolic syndrome. The Atherosclerosis Risk in Communities Study (ARIC). Circulation 2008, 117:754\u2013761.","journal-title":"Circulation"},{"key":"59_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.0000125726.92964.ab","volume":"43","author":"P. Verdecchia","year":"2004","unstructured":"Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:1\u20137.","journal-title":"Hypertension"},{"key":"59_CR22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2337\/dc05-2366","volume":"29","author":"E.N. Taylor","year":"2006","unstructured":"Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065\u20131070.","journal-title":"Diabetes Care"},{"key":"59_CR23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1559-4564.2007.888142.x","volume":"2","author":"M. Shargorodsky","year":"2007","unstructured":"Shargorodsky M, Boaz M, Davidovitz I, et al.: Treatment of hypertension with thiazides: benefit or damage-effect of low-and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance. J Cardiometab Syndr 2007, 2:16\u201323.","journal-title":"J Cardiometab Syndr"},{"key":"59_CR24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11906-006-0086-8","volume":"8","author":"S. Stas","year":"2006","unstructured":"Stas S, Appesh L, Sowers JR: Metabolic safety of antihypertensive drugs: myth vs. reality. Curr Hypertens Rep 2006, 8:403\u2013408.","journal-title":"Curr Hypertens Rep"},{"key":"59_CR25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1524-6175.2005.04144.x","volume":"7","author":"B.L. Carter","year":"2005","unstructured":"Carter BL, Basile J: Development of diabetes with thiazide diuretics: the potassium issue. J Clin Hypertens 2005, 7:638\u2013640.","journal-title":"J Clin Hypertens"},{"key":"59_CR26","first-page":"221","volume":"28","author":"J. Stevo","year":"2004","unstructured":"Stevo J, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: VALUE randomised trial. Lancet 2004, 28:221\u2013226.","journal-title":"Lancet"},{"key":"59_CR27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","volume":"168","author":"J.T. Wright","year":"2008","unstructured":"Wright JT, Harris-Haywood S, Pressel S, et al.: Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008, 168:207\u2013217.","journal-title":"Arch Intern Med"},{"key":"59_CR28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.ten.0000146262.10013.e7","volume":"14","author":"A.S. Tan","year":"2004","unstructured":"Tan AS, Kuppuswamy S, Whaley-Connell AT, et al.: Recommendations for special populations: the treatment of hypertension in diabetes mellitus. Endocrinologist 2004, 14:368\u2013381.","journal-title":"Endocrinologist"},{"key":"59_CR29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.amjhyper.2007.01.019","volume":"20","author":"A.J. Bank","year":"2007","unstructured":"Bank AJ, Kelly AS, Thelen AM, et al.: Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hyperten 2007, 20:777\u2013783.","journal-title":"Am J Hyperten"},{"key":"59_CR30","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","volume":"292","author":"G.L. Bakris","year":"2004","unstructured":"Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227\u20132236.","journal-title":"JAMA"},{"key":"59_CR31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.hjh.0000209993.26057.de","volume":"24","author":"T. Celik","year":"2006","unstructured":"Celik T, Iyisoy A, Kursaklioglu H, et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertension 2006, 24:591\u2013596.","journal-title":"J Hypertension"},{"key":"59_CR32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","volume":"25","author":"A. Villamil","year":"2007","unstructured":"Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217\u2013226.","journal-title":"J Hypertens"},{"key":"59_CR33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.ki.5002732","volume":"73","author":"F.C. Luft","year":"2008","unstructured":"Luft FC, Weinberger MH: Antihypertensive therapy with aliskiren. Kidney Int 2008, 73:679\u2013683.","journal-title":"Kidney Int"},{"key":"59_CR34","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2337\/diacare.28.9.2261","volume":"28","author":"E.L. Gillespie","year":"2005","unstructured":"Gillespie EL, White CM, Kardas M, et al.: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261\u20132266.","journal-title":"Diabetes Care"},{"key":"59_CR35","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","volume":"355","author":"J. Bosch","year":"2006","unstructured":"Bosch J, Yusuf S, Gerstein HC, et al.; DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551\u20131562.","journal-title":"N Engl J Med"},{"key":"59_CR36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A. Patel","year":"2007","unstructured":"Patel A, ADVANCE Collaborative Group, MacMahon S, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829\u2013840.","journal-title":"Lancet"},{"key":"59_CR37","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","volume":"359","author":"L.H. Lindholm","year":"2002","unstructured":"Lindholm LH, Ibsen H, Dahlof B, et al.; LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004\u20131010.","journal-title":"Lancet"},{"key":"59_CR38","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","volume":"21","author":"L.H. Lindholm","year":"2003","unstructured":"Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertension 2003, 21:1563\u20131574.","journal-title":"J Hypertension"},{"key":"59_CR39","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2169\/internalmedicine.46.7173","volume":"46","author":"Y. Ichikawa","year":"2007","unstructured":"Ichikawa Y: Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007, 46:1331\u20131336.","journal-title":"Intern Med"},{"key":"59_CR40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B. Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"59_CR41","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"59_CR42","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1210\/en.2006-1691","volume":"148","author":"S. Stas","year":"2007","unstructured":"Stas S, Whaley-Connell A, Habibi J, et al.: Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007, 148:3773\u20133780.","journal-title":"Endocrinology"},{"key":"59_CR43","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","volume":"111","author":"A. Fiebeler","year":"2005","unstructured":"Fiebeler A, Nussberger J, Shagdarsuren E, et al.: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087\u20133094.","journal-title":"Circulation"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0059-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-008-0059-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0059-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:21Z","timestamp":1559434461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-008-0059-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1007\/s11906-008-0059-1","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}